文献速递淋巴瘤

慢性淋巴细胞白血病随机临床试验设计中的跳步现象

Skipping a step: what happened to the design of randomized clinical trials in chronic lymphocytic leukaemia?
PubMed 文献 · Br J Haematol · 2020-11-20

该文评述慢性淋巴细胞白血病(CLL)随机试验在设计上跳过新药单药测试、直接进入联合方案的现象。作者指出伊布替尼联合利妥昔单抗等联合方案虽被采用,但后续试验显示加用利妥昔单抗无有意义获益,导致单克隆抗体组分的真实作用不确定,呼吁未来试验采用逐步设计。

要点

  • CLL随机试验跳过新药单药测试,直接评估联合方案。
  • 伊布替尼联合利妥昔单抗作为实验臂,但后续试验显示加用利妥昔单抗无有意义获益。
  • 未来随机试验应采用逐步设计,以明确新方案疗效。

核心结论

  • CLL随机试验跳过新药单药测试直接进入联合方案,导致单克隆抗体组分的真实作用不确定。
  • 未来随机试验应采用逐步设计,以提供新方案疗效的稳健答案。

研究设计与样本

  • 本文为评述文章,讨论CLL随机临床试验的设计问题。

主要发现

  • 伊布替尼联合利妥昔单抗被用作初治fit患者的实验臂,但两项其他试验随后显示加用利妥昔单抗无有意义获益。
  • 两项大型试验省略维奈克拉单药治疗,直接比较维奈克拉联合利妥昔单抗或奥妥珠单抗与化学免疫治疗。
  • 此类试验更便宜、快速和易于管理,但遗留单克隆抗体组分真实作用的不确定性。

关键数值与推荐

  • 伊布替尼联合利妥昔单抗被用作初治fit患者的实验臂。
  • 两项其他试验显示加用利妥昔单抗至伊布替尼不产生任何有意义获益。
  • 两项大型试验省略维奈克拉单药治疗,直接评估维奈克拉联合利妥昔单抗或奥妥珠单抗对比化学免疫治疗。

临床怎么用

  • 当前方案有效但可能不必要地毒性和昂贵,临床应关注联合方案中单克隆抗体组分的必要性。
  • 未来试验设计应采用逐步方式,以明确新方案疗效后再引入实践。

局限性

  • 本文为评述文章,未报告原始研究数据或系统检索方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Clinical research of chronic lymphocytic leukaemia (CLL) has been advancing at an unprecedented pace. Several randomized studies in the current era of oral targeted agents seem to have skipped one step and proceeded directly to combinations with antibodies, omitting the testing of novel-agent monotherapy. Thus, the ibrutinib + rituximab combination was used as the experimental arm in a major trial for untreated fit patients while two other trials subsequently showed that addition of rituximab to ibrutinib does not produce any meaningful benefit. Similarly, two large trials omitted venetoclax monotherapy and proceeded directly to venetoclax + rituximab or obinutuzumab versus chemoimmunotherapy. While such trials are undoubtedly cheaper, quicker and easier to manage, they leave the CLL community with uncertainty regarding the real role of the monoclonal antibody components. Thus, we are left with regimens which are undoubtedly effective, but might actually be unnecessarily toxic and expensive. The solution to this problem is simple: future randomized trials should be carefully designed in a 'step by step' fashion which would provide the CLL community with simple yet robust answers regarding efficacy of novel regimens so that these can be introduced to practice following the best principles of evidence-based medicine.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Smolej L. Skipping a step: what happened to the design of randomized clinical trials in chronic lymphocytic leukaemia? Br J Haematol. 2020. PMID: 33216352. doi:10.1111/bjh.17215

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。